Showing results (321-330 of 941) with videos related to
Sort By:
Pageof 95
Diabetes & Vascular Disease Research|May 4, 2017
Chronic NaHS treatment decreases oxidative stress and improves endothelial function in diabetic miceHooi H Ng, Gunes S Yildiz, Jacqueline M Ku, et al.Diabetes & Vascular Disease Research|June 19, 2018
Risk factors for the development of micro-vascular complications of type 2 diabetes in a single-centre cohort of patientsMarsida Teliti, Giulia Cogni, Lucia Sacchi, et al.Diabetes & Vascular Disease Research|June 1, 2018
Haemoglobin A1c variability as an independent correlate of atherosclerosis and cardiovascular disease in Chinese type 2 diabetesYifei Mo, Jian Zhou, Xiaojing Ma, et al.Diabetes & Vascular Disease Research|January 22, 2009
Circulating soluble CD36 is associated with glucose metabolism and interleukin-6 in glucose-intolerant menAase Handberg, Abel Lopez-Bermejo, Judit Bassols, et al.Diabetes & Vascular Disease Research|January 22, 2009
Is nuclear magnetic resonance lipoprotein subclass related to diabetic retinopathy? The multi-ethnic study of atherosclerosis (MESA)Andreas J Kreis, Tien Yin Wong, F M Amirul Islam, et al.Diabetes & Vascular Disease Research|January 22, 2009
The effect of rosiglitazone on integrated cardiovascular performance, cardiac structure, function and myocardial triglyceride: trial design and rationaleDarren K McGuire, Raphael See, Shuaib M Abdullah, et al.Diabetes & Vascular Disease Research|November 21, 2007
The role of fenofibrate in clinical practiceAlberto Zambon, Kenneth CusiDiabetes & Vascular Disease Research|November 21, 2007
Clinical implications of the metabolic syndromeRichard CeskaDiabetes & Vascular Disease Research|December 13, 2006
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetesBrian D Green, Peter R Flatt, Clifford J BaileyDiabetes & Vascular Disease Research|December 13, 2006
Fibrates after the FIELD study: Some answers, more questionsAnthony S WierzbickiPageof 95